PMID- 26870301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 11
IP  - 1
DP  - 2016 Jan
TI  - Re-evaluation of various molecular targets located on CD34(+)CD38(-)Lin(-) 
      leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia.
PG  - 891-897
AB  - Leukemia stem cells (LSCs) are hypothesized to be capable of driving the 
      development of leukemia, and are responsible for disease relapse. Antibody 
      therapy targeting cell surface antigens has significantly improved the treatment 
      outcomes of leukemia. Therefore, it is important to identify cell surface markers 
      that are expressed on LSCs, and that are unexpressed or expressed at reduced 
      levels on normal hematopoietic stem cells (HSCs), in order to establish novel 
      therapeutic targets. In the present study, the immunophenotypic characteristics 
      of cluster of differentiation (CD)34(+)CD38(-)lineage (Lin)(-) stem cells were 
      analyzed, and antigen expression levels were compared with the expression of 
      other cell components, using multicolor flow cytometry, in 54 patients with newly 
      diagnosed acute myeloid leukemia (AML) and 11 control patients with immune 
      thrombocytopenia. The findings indicated that CD133 and human leukocyte antigen 
      (HLA)-DR were expressed on normal HSCs and on AML LSCs, with no significant 
      difference (P>0.05). By contrast, CD33, CD123 and CD44 were highly expressed on 
      AML LSCs, and demonstrated significant differences compared with their expression 
      on normal HSCs (CD33, 81.7 vs. 18.3%; CD123, 75.8 vs. 19.1%; CD44, 97.7 vs. 
      84.4%). Among the aforementioned antigens, CD33 and CD123 were promising 
      candidates for targeted therapy for the treatment of AML. This was particularly 
      evident for CD123 in immature AML subtype cells, which may require additional 
      investigation within a clinical trial setting. CD44, CD133 and HLA-DR may not be 
      suitable for leukemia targeting due to their broad and high expression levels on 
      normal HSCs and other tissues.
FAU - Cheng, Yuping
AU  - Cheng Y
AD  - Department of Hematology-Oncology, Children's Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Jia, Ming
AU  - Jia M
AD  - Department of Hematology-Oncology, Children's Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Chen, Yuanyuan
AU  - Chen Y
AD  - Department of Hematology-Oncology, Children's Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Zhao, Haizhao
AU  - Zhao H
AD  - Department of Hematology-Oncology, Children's Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Luo, Zebin
AU  - Luo Z
AD  - Department of Hematology-Oncology, Children's Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
FAU - Tang, Yongmin
AU  - Tang Y
AD  - Department of Hematology-Oncology, Children's Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20151125
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4726975
OTO - NOTNLM
OT  - childhood acute myeloid leukemia
OT  - cluster of differentiation antigen
OT  - flow cytometry
OT  - hematopoietic stem cells
OT  - leukemia stem cells
EDAT- 2016/02/13 06:00
MHDA- 2016/02/13 06:01
PMCR- 2015/11/25
CRDT- 2016/02/13 06:00
PHST- 2014/11/18 00:00 [received]
PHST- 2015/10/02 00:00 [accepted]
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/02/13 06:01 [medline]
PHST- 2015/11/25 00:00 [pmc-release]
AID - OL-0-0-3972 [pii]
AID - 10.3892/ol.2015.3972 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Jan;11(1):891-897. doi: 10.3892/ol.2015.3972. Epub 2015 Nov 25.